{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:54:45Z","timestamp":1790765685206,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by reduced platelet counts. Dupilumab, an IL-4 receptor antagonist, is effective in allergic and auto-inflammatory diseases; however, use in ITP remains unexplored. Case Presentation: A 78-year-old male with chronic ITP, maintained on a thrombopoietin receptor agonist (TPO-RA) with an average platelet count of around 78,000\/\u03bcL, demonstrated a sustained rise in platelet counts (&gt;100,000\/\u03bcL) shortly following initiation of dupilumab for an unrelated chronic obstructive pulmonary disease. This improvement enabled a stepwise reduction in TPO-RA to &lt;20% of his base dosage while maintaining adequate platelet levels for three years since. Despite detailed patient interviews and chart review, we were unable to identify any clinical factors besides commencement of dupilumab as a potential explanation. If indeed causative, we speculate that a TPO-RA-sparing effect of dupilumab might occur via disruption of IL-4 signaling, leading to inhibited Th9 cell activation and subsequent IL-21 production to restore Treg\/Th17 balance, thus contributing to decreased platelet destruction. Discussion: This case supports a potential role for dupilumab in the treatment of chronic ITP. To our knowledge, it is the first report suggesting a therapeutic benefit of IL-4 blockade in this disease. Identification of predictive immunologic biomarkers, such as cytokine profiles or T-cell subset signatures, might help identify patients most likely to benefit from IL-4 pathway modulation. Further controlled studies are warranted to clarify the immunologic mechanisms underlying this response and to assess the therapeutic potential of targeting the IL-4 axis in ITP.<\/jats:p>","DOI":"10.3390\/jcm15197539","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:50:54Z","timestamp":1790614254000},"page":"7539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Platelet Improvement Temporally Associated with Dupilumab in Chronic Immune Thrombocytopenia: A Case Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2431-9566","authenticated-orcid":false,"given":"Xinyu","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, VA Puget Sound Healthcare System, Seattle, WA 98108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-8952","authenticated-orcid":false,"given":"Nicholas R.","family":"Burwick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Divisions of Hematology, Oncology and Bone Marrow Transplantation, VA Puget Sound Healthcare System, Seattle, WA 98108, USA"},{"name":"Department of Medicine, Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-2634","authenticated-orcid":false,"given":"Sarah K.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Zag Bio, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-7809","authenticated-orcid":false,"given":"Aaron B.","family":"Boothby","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6178-1117","authenticated-orcid":false,"given":"Vincent S.","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care, VA Puget Sound Health Care System, Seattle, WA 98108, USA"},{"name":"Department of Medicine, Division of Pulmonary, Critical Care, & Sleep Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-0550","authenticated-orcid":false,"given":"Jesse J.","family":"Salk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Divisions of Hematology, Oncology and Bone Marrow Transplantation, VA Puget Sound Healthcare System, Seattle, WA 98108, USA"},{"name":"Department of Medicine, Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Clinical Research Division and Translational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104096","DOI":"10.1016\/j.cellimm.2020.104096","article-title":"CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopenia","volume":"351","author":"Kostic","year":"2020","journal-title":"Cell Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: The phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"ref_5","unstructured":"Regeneron Pharmaceuticals, Inc. (2026, June 02). Dupixent (Dupilumab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2024\/761055s043lbl.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.htct.2023.03.022","article-title":"IL-4R\u03b1 (rs1801275) A>G polymorphism in Egyptian immune thrombocytopenia (ITP) patients: A single center experience","volume":"46","author":"Morad","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood.V128.22.3739.3739","article-title":"Th2 cytokine polymorphisms, IL-4 -590 CC genotype and IL-10RB K47E, increase the requirement of second-line treatment for chronic ITP","volume":"128","author":"Kitamura","year":"2016","journal-title":"Blood"},{"key":"ref_8","unstructured":"AstraZeneca Pharmaceuticals LP (2026, June 02). Fasenra (Benralizumab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2024\/761070s013lbl.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00431-023-04945-x","article-title":"Role of interleukin 4 (IL4) and interleukin 6 (IL6) in the pathogenesis and prognosis of childhood primary immune thrombocytopenia","volume":"182","author":"Zakaria","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2024.11.031","article-title":"Inborn errors of immunity reveal molecular requirements for generation and maintenance of human CD4+ IL-9-expressing cells","volume":"155","author":"Rao","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/09537104.2016.1218454","article-title":"An increased expression profile of Th9\/IL-9 correlated with Th17\/IL-17 in patients with immune thrombocytopenia","volume":"28","author":"Qiao","year":"2017","journal-title":"Platelets"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2014-03-563445","article-title":"Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia","volume":"124","author":"Audia","year":"2014","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/intimm\/dxab080","article-title":"The role of IL-4 derived from follicular helper T (TFH) cells and type 2 helper T (TH2) cells","volume":"33","author":"Kubo","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"adv00409","DOI":"10.2340\/00015555-3734","article-title":"Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab","volume":"101","author":"Frey","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_15","first-page":"e16658","article-title":"An Uncharacteristic Presentation of Evans Syndrome Following Treatment with Dupilumab","volume":"13","author":"Rutherford","year":"2021","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1038\/s41598-020-68647-2","article-title":"Relationship of primary immune thrombocytopenic purpura and atopia among children: A case control study","volume":"10","author":"Bahoush","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","unstructured":"Novartis Pharmaceuticals Corporation (2026, August 30). Promacta (eltrombopag) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207027s014lbl.pdf."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2026, June 02). Orphan Drug Product Designation Database. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=599317."},{"key":"ref_21","unstructured":"Veterans Health Administration (2026, June 08). About Us. U.S. Department of Veterans Affairs, Available online: https:\/\/department.va.gov\/vha\/about-us\/."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:54:33Z","timestamp":1790762073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":21,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197539"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197539","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}